Wednesday, 4 December 2024

08:00-09:45

Registration

09:45-10:00

Welcome, introduction and objectives

Ana Giménez-Arnau, Torsten Zuberbier , Emek Kocatürk, Luis Ensina 

Keynote lecture session I: Pathophysiology of CSU:

10:00-10:25

Chronic spontaneous urticaria: Update on pathophysiology

Sarbjit Saini and Michihiro Hide

10:25-10:50

Non-IgE-mediators and neurogenic activation of mast cells

Martin Metz and Young Min Ye

Oral presentation session I: Aetiopathogenesis of urticaria, differential diagnosis, comorbidities and diagnostic approaches

10:50-10:59

10:59-11:08

11:08-11:17

11:17-11:26

11:26-11:35

OP. 001 | The role of T-cell-mast-cell cross talk and proximity in the pathogenesis  of chronic spontaneous urticaia

Elias Toubi

OP. 002 | Relevance of the basophil activation test in a cohort of 240 patients with chronic spontaneous urticaria

David Pesqué

OP. 003 | Development of a rapid and portable test for the measurement of anti-TPO IgE in clinical practice. Proof of concept.

Jorge Sanchez

OP. 004 | Depletion of mast cells with barzolvolimab, an anti-KIT antibody, does not affect mast cell progenitor numbers or function

Sherezade Moñino-Romero

OP. 005 | CD300 receptor: A new target in the pathogenesis of autoimmune urticaria?

Ozge Sevil Karstarli Bakay

11:36-12:00

Coffee break

EMBRN session: The biology of mast cells and basophils and their role in health and disease

12:00-12:05

EMBRN introduction

Frank Siebenhaar and Francesca Levi-Schaffer

12:05-12:20

The evolving story of the allergic effector unit

Francesca Levi-Schaffer

12:20-12:35

Mast cells and tissue infiltrating immune cells

Stefan Frischbutter

12:35-12:50

Mast cells in the skin: enemies driving inflammation or defenders of integrity?

Anne Dudeck

12:50-12:55

Summary

Frank Siebenhaar and Francesca Levi-Schaffer

12:55-13:55

Sponsored Symposium

13:55-14:25

Lunch break

Keynote lecture session II: Endotypes and biomarkers of CU

14:25-14:50

Endotypes of CSU – What we know and what we don´t know

Pavel Kolkhir and Riccardo Asero

14:50-15:15

Biomarkers of CU clinical behavior and therapy response to available treatments 

Desire Larena Linnemann and Luis Ensina

Oral presentation session II: Urticaria treatments, predictors of response and biomarkers in CU

15:15-15:24

15:24-15:33

15:33-15:42

15:42-15:51

15:51-16:00

OP. 006 | EVO756, an oral MRGPRX2 antagonist, is well-tolerated and demonstrates target engagement: Topline results from a phase 1 study 

Sarbjit S. Saini

OP. 007 | Prognostic value of novel in-vitro variables for severe CSU responding and not responding to omalizumab 

Riccardo Asero

OP. 008 | Barzolvolimab shows profound efficacy and favorable safety over 52 weeks in patients with chronic spontaneous urticaria

Martin Metz

OP. 009 | Rilzabrutinib reduces severity of weekly urticaria activity score in patients with chronic spontaneous urticaria in RILECSU phase 2 trial

Ana Maria Giménez-Arnau

OP. 010 | Safety and efficacy of remibrutinib in japanese patients with chronic spontaneous urticaria (BISCUIT study interim analysis)

Koremasa Hayama

14:49-14:58

OP.007  PREDICT-CU: Predicting time to clinical remission in chronic urticaria
Maria-Magdalena Balp (Switzerland)

14:07-15:16

OP.009  Urticaria in patients with suspected mast cell activation syndrome
Fabiana Nunes Oliveira (Brazil)

14:58-15:07

OP.008  Remibrutinib inhibits mastcell and basophil activation in chronic urticaria independently of FcεR1 expression
Ana Giménez-Arnau (Spain)

14:16-15:25

OP.010  In chronic spontaneous urticaria, fever, pain and malaise are common and linked to active and uncontrolled disease: Results from the Chronic Urticaria Registry (CURE)
Polina Pyatilova (Germany)

16:02-16:35

Coffee break 

Poster walks and poster session

16:35-17:35

Poster walks and poster session

In recognition of the great person, Marcus Maurer.

17:35-18:35

The history of modern urticaria and a tribute to Marcus Maurer

Oral Presentation Session III: Urticaria treatments and predictors of response

16:20-16:40

What’s new?

16:40-17:25

Oral Presentations

17:49-17:58

OP.012 Long-term safety of remibrutinib in CSU patients: Phase 2b study
Ana Giménez-Arnau (Spain)

17:58-18:07

OP.013 Dupilumab Efficacy in Patients with Chronic Spontaneous Urticaria with Comorbidities
Marcus Maurer (Germany)

18:07-18:16

OP.014 Cold urticaria patients achieve complete response with 1.5 mg/kg barzolvolimab
Dorothea Terhorst-Molawi (USA)

18:16-18:25

OP.015 Elevated levels of soluble FcεRI as a biomarker of early and good response to omalizumab treatment in chronic spontaneous urticaria
Sherezade Moñino-Romero (Germany)

18:25-18:34

OP.016 Differences between pediatric and adult urticaria: patient characteristics, treatment response and indicators of response
Sinem Ornek Ozdemir (Turkey)

18:34-18:43

OP.017 Autoimmunity and low IgE in CSU: a prospective analysis
David Pesqué (Spain)

18:43-18:52

OP.018 Anti-TPO/total IgE ratio – biomarker for omalizumab response prediction in CSU
Rita Brás (Portugal)

18:35

Scientific Dinner